Adeno-associated viruses (AAVs) continue to be a foundational platform for gene therapies, with rapid advances in vector design, analytics, and manufacturing practices. This three-part USP webinar ...
The alternative text for this image may have been generated using AI. We first analyzed the six AAV2 capsid mutants (I-261, I-381, I-447, I-534, I-573 and I-587) for their ability to package the viral ...
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major ...
VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations highlight Voyager’s ...
International HIV publication further validates the DeepChek® brand for HIV genotyping and long- & short-read NGS, ...
Research Describes the Potential of JCR’s Platform Technologies, Including JUST-AAV Gene Therapy, to Facilitate Delivery of Therapies to the Central Nervous System -HYOGO, Japan--(BUSINESS WIRE)--JCR ...
Affinia Therapeutics ("Affinia"), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for ...
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced the launch of two new ...
USP recognizes CryoTEM for characterizing empty/full/intermediate capsids on AAV8 reference standards STOCKHOLM, ...
Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results